Y Intercept Hong Kong Ltd Has $1.39 Million Stock Holdings in Solventum Corporation $SOLV

Y Intercept Hong Kong Ltd decreased its holdings in shares of Solventum Corporation (NYSE:SOLV) by 72.5% in the first quarter, Holdings Channel reports. The firm owned 21,297 shares of the company’s stock after selling 56,226 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Solventum were worth $1,391,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of SOLV. Davis Selected Advisers raised its stake in Solventum by 0.5% during the third quarter. Davis Selected Advisers now owns 5,517,611 shares of the company’s stock worth $402,786,000 after acquiring an additional 24,950 shares in the last quarter. Appleton Partners Inc. MA bought a new position in shares of Solventum during the fourth quarter valued at $7,008,000. SG Americas Securities LLC boosted its stake in shares of Solventum by 92.3% in the 4th quarter. SG Americas Securities LLC now owns 93,681 shares of the company’s stock valued at $7,423,000 after purchasing an additional 44,970 shares in the last quarter. Independent Franchise Partners LLP boosted its stake in shares of Solventum by 27.2% in the 3rd quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock valued at $941,645,000 after purchasing an additional 2,758,174 shares in the last quarter. Finally, KBC Group NV grew its holdings in shares of Solventum by 52.0% in the 4th quarter. KBC Group NV now owns 462,417 shares of the company’s stock worth $36,642,000 after purchasing an additional 158,242 shares during the last quarter.

Solventum Price Performance

Solventum stock traded up $0.76 on Friday, reaching $76.72. The company’s stock had a trading volume of 532,926 shares, compared to its average volume of 1,263,437. The business’s fifty day moving average price is $76.24 and its 200 day moving average price is $74.32. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. The company has a market cap of $13.29 billion, a price-to-earnings ratio of 9.40, a PEG ratio of 1.17 and a beta of 0.66. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $88.20.

Solventum (NYSE:SOLV) last announced its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same period last year, the company posted $1.34 earnings per share. The firm’s quarterly revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Equities analysts expect that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. KeyCorp increased their target price on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Stifel Nicolaus reduced their price target on shares of Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Wedbush began coverage on shares of Solventum in a research note on Friday, May 15th. They set an “outperform” rating and a $94.00 price objective on the stock. Piper Sandler dropped their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Finally, Rothschild & Co Redburn began coverage on shares of Solventum in a report on Tuesday, March 24th. They set a “sell” rating and a $60.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $83.50.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.